These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 17950105

  • 1. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 3. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
    Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L.
    Free Radic Biol Med; 2007 Mar 01; 42(5):698-705. PubMed ID: 17291993
    [Abstract] [Full Text] [Related]

  • 4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 01; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 5. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 6. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.
    Eur J Clin Invest; 2006 Aug 01; 36(8):560-5. PubMed ID: 16893378
    [Abstract] [Full Text] [Related]

  • 7. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 01; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 8. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.
    Am J Cardiol; 2008 Nov 15; 102(10):1341-7. PubMed ID: 18993152
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
    Chatley P, Badyal DK, Calton R, Khosla PP.
    Methods Find Exp Clin Pharmacol; 2007 Apr 15; 29(3):217-21. PubMed ID: 17520105
    [Abstract] [Full Text] [Related]

  • 10. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 15; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 11. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May 15; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 12. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
    Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Mar 15; 57(3):380-6. PubMed ID: 18249211
    [Abstract] [Full Text] [Related]

  • 13. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 15; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 15; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Nov 02; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 15; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 19. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G, Fellin R.
    Nutr Metab Cardiovasc Dis; 2005 Feb 15; 15(1):47-55. PubMed ID: 15871851
    [Abstract] [Full Text] [Related]

  • 20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 15; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.